Fecal microbiota transplantation in obesity metabolism: A meta analysis and systematic review

Diabetes Res Clin Pract. 2023 Aug:202:110803. doi: 10.1016/j.diabres.2023.110803. Epub 2023 Jun 24.


Objective: The effect of fecal microbiota transplantation (FMT) on microbiota engraftment in patients with metabolic syndrome remains unclear. This systematic review employed a meta-analysis of RCTs for assessment on the role of FMT in treating obesity and metabolic syndrome, and its impact on clinically relevant parameters.

Method: Major databases and grey literatures were searched identifying RCTs comparing FMT of lean donors with placebo in obese/metabolic syndrome patients. Studies using any form of placebo were included. Variations in the parameters before and after treatment were calculated followed by meta-analyses.

Result: Ten studies met the inclusion criteria and a total of 334 patients were included for further analysis. Clinically significant parameters associated with obesity and metabolic syndrome were explored and FMT was identified significantly and negatively associated with most indices of abdominal adiposity including caloric intake, fasting glucose, HOMA-IR, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL, LDL, triglycerides and CRP, Obesity parameters including fasting glucose and acetic acid were increased following FMT.

Conclusion: FMT is more advantageous for obese patients with elevated blood pressure, disordered glucose and insulin metabolism, and elevated blood lipids. The study of metabolic factors in obese patients will be our starting point in the future.

Keywords: Fecal microbiota transplantation; Meta-analysis; Obesity.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Fecal Microbiota Transplantation*
  • Glucose / metabolism
  • Humans
  • Lipids
  • Metabolic Syndrome* / therapy
  • Obesity / metabolism
  • Obesity / therapy


  • Glucose
  • Lipids